Royal Bank of Canada Sells 18,448 Shares of LeMaitre Vascular, Inc. $LMAT

Royal Bank of Canada reduced its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.3% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 272,654 shares of the medical instruments supplier’s stock after selling 18,448 shares during the quarter. Royal Bank of Canada’s holdings in LeMaitre Vascular were worth $29,765,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in LeMaitre Vascular by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after acquiring an additional 21,946 shares during the period. Conestoga Capital Advisors LLC lifted its position in shares of LeMaitre Vascular by 3.6% during the first quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock worth $161,224,000 after acquiring an additional 51,825 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of LeMaitre Vascular by 6.2% in the first quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock worth $108,959,000 after acquiring an additional 57,931 shares during the period. State Street Corp boosted its holdings in shares of LeMaitre Vascular by 0.8% in the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after acquiring an additional 6,130 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of LeMaitre Vascular by 20.1% in the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after purchasing an additional 105,921 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the transaction, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridget A. Ross sold 5,044 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $111.10, for a total value of $560,388.40. Following the transaction, the director owned 3,942 shares in the company, valued at $437,956.20. This trade represents a 56.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 54,453 shares of company stock valued at $5,906,174 over the last 90 days. 7.40% of the stock is owned by insiders.

LeMaitre Vascular Trading Up 2.1%

Shares of LeMaitre Vascular stock opened at $105.78 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. LeMaitre Vascular, Inc. has a 1 year low of $79.39 and a 1 year high of $118.01. The firm has a market cap of $2.42 billion, a PE ratio of 39.03, a PEG ratio of 2.88 and a beta of 0.53. The company has a 50 day simple moving average of $97.41 and a two-hundred day simple moving average of $100.04.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The company had revenue of $70.38 million during the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.LeMaitre Vascular’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.60 EPS. Analysts expect that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio is currently 36.90%.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue rose 9.6% year over year to $70.38 million, while EPS increased from $0.60 to $0.74. The company also reported a healthy 24.35% net margin and announced a quarterly dividend of $0.25 per share. LeMaitre Q2 2026 Financial Results
• Neutral Sentiment: Management projected fourth-quarter 2026 EPS of $0.75–$0.81, broadly around the $0.79 analyst consensus, suggesting some potential for results to meet expectations later in the year.
• Negative Sentiment: Second-quarter EPS of $0.74 missed the $0.81 consensus estimate, and revenue of $70.38 million came in below the $71.47 million forecast. LeMaitre Vascular Earnings Results
• Negative Sentiment: Full-year 2026 guidance was reduced to EPS of $2.84–$2.94 and revenue of $274.3 million–$278.3 million, below consensus estimates of $3.00 EPS and $279.9 million revenue.
• Negative Sentiment: Third-quarter guidance also trailed expectations, with EPS of $0.66–$0.71 versus $0.73 consensus and revenue of $66.3 million–$68.3 million versus $69.0 million expected.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LMAT shares. Citizens Jmp boosted their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Barrington Research reiterated an “outperform” rating and set a $120.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Wells Fargo & Company increased their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus price target of $112.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.